Search

Search Results

• Book

  Essential writing, communication and narrative skills for medical scientists before and after the COVID era

  Gian Carlo Di Renzo, editor.

  Summary: When the COVID- 19 pandemic occurred, all the main communication systems of medical research have undergone an epochal change. Many online journals and magazines have tried to publish inherent works of this specific problem as soon as possible, soliciting and preferring them to others, thus changing the system of free acceptance of scientific works once. Moreover, the way to communicate these works has no longer occurred through standard Scientific Congresses but with other systems, websites/streaming and webinars or virtual conferences. Now there is something systematic missing, which foresees that this may last in the future, in the post COVID-19 era (AC): the communication system of the medical sciences will be different from now on. There will be far fewer classical-style conferences like the ones so popular before COVID-19 outbreak (BC) but there will be more webinars, in streaming and virtual conferences. This new book fits well in this period, creating a bridge between those who do research, how it is communicated, what are the classic communication methods and what is all the necessary background to communicate with new tools. The book idea is based on the legacy left by Michael Faraday, the famous American chemist, who sensed how communicating what happens in science can make the difference between the success and failure of the research itself.
  
  Contents:
  The Island Of Research (Do Not Block The Path Of Enquiry)
  Big Data, Metanalysis And Sistematic Reviews : The Jungle Of Statistics
  Essentials On Writing A Paper For A Peer Reviewed Journal
  The Value Of The Websites And Online Journals
  Ways To Implement Your Key Messages
  The Classical Meetings And Congresses
  The New Ways To Communicate Your Research: Webinars And Beyond
  The Virtual Theatre : The Lure, The Title, The Scene, The Backstage, The Space
  The World Of Audience : Listeners Or Gazers, Learned Or Unlearned
  Connect And Be Understood
  Narrative Science And Medicine
  The Legacy Of Michael Faraday.

  Digital Access Springer 2022
  Get Shareable Link

  View Details
• Article

  Efficacia e tollerabilità dell'atenololo beta-bloccante cardioselettivo nel trattamento dell'ipertensione arteriosa essenziale. Studio a doppio cieco. [Efficacy and tolerability of a cardioselective beta-blocking drug (atenolol) in the treatment of essential hypertension. A double blind study (author's transl)].

  Rengo F, Trimarco B, Petretta M, Ferrara N, Bonaduce D, Chiariello M, Condorelli M.

  G Ital Cardiol. 1978;8(8):861-7.

  The antihypertensive effect of atenolol, a new beta 1 receptor blocking agent, was studied in a double blind non cross-over trial in 40 patients (pts) affected by mild to moderately severe essential hypertension with normal plasma renin activity. After a run-in period (15 days) of placebo treatment pts were assigned to two groups. The first (group A) continued placebo treatment for 30 days, the second (Group B) were given atenolol (ICI 66082) 100 mg daily for 30 days also. Atenolol significantly reduced systolic and diastolic blood pressure in recumbent and standing position and heart rate at rest. No significantly changes of the same parameters were observed in group A. Body weight and plasma renin activity was unchanged in both groups. Atenolol treatment never was discharged in order to side effects. These results seem to suggest that atenolol can be an useful drug in the treatment of systemic blood hypertension.

  Digital Access Access Options
  Get Shareable Link

  PubMed